drugset
drugset / Trial / NCT04164719

Dose-Proportionality and Food Effect Study of TNX-102 SL

NCT04164719 ↗

Phase 1 Completed 16 enrolled Tonix Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelOther

Summary

This will be a single center, single-dose, randomized, open-label, 3-period, crossover, dose-proportionality and food-effect study.

Timeline

Start
2019-10-14
Primary completion
2019-12-24
Completion
2019-12-24

Drugs

EvaluationDrugModalityDoseRoute
Subject cyclobenzaprine Small molecule 2.8 mg Other
Subject cyclobenzaprine Small molecule 5.6 mg Other

Indications

No indication recorded.